Saranac Partners Ltd Raises Stock Holdings in Cencora, Inc. $COR

Saranac Partners Ltd increased its stake in Cencora, Inc. (NYSE:COR) by 787.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,837 shares of the company’s stock after purchasing an additional 4,292 shares during the period. Saranac Partners Ltd’s holdings in Cencora were worth $1,634,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Oakworth Capital Inc. purchased a new stake in shares of Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in Cencora during the fourth quarter valued at about $27,000. Archer Investment Corp lifted its stake in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. Optima Capital LLC bought a new stake in Cencora during the fourth quarter worth about $31,000. Finally, IAG Wealth Partners LLC purchased a new position in shares of Cencora in the 3rd quarter worth about $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

COR has been the subject of a number of recent research reports. Barclays boosted their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Evercore set a $360.00 price objective on shares of Cencora in a report on Wednesday, April 8th. Citigroup reduced their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research note on Monday, May 4th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $380.25.

Cencora Stock Performance

Cencora stock opened at $266.03 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The firm has a 50-day moving average of $310.87 and a 200-day moving average of $338.24. The firm has a market cap of $51.76 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.21 and a beta of 0.64. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is 18.40%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.